130 related articles for article (PubMed ID: 16525490)
21. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
[TBL] [Abstract][Full Text] [Related]
22. Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation.
Martín-Palanco V; Martínez F; Arqueros V; Torres A; Román-Gómez J
Eur J Haematol; 2011 Aug; 87(2):182-5. PubMed ID: 21762210
[No Abstract] [Full Text] [Related]
23. [Autologous transplantation of peripheral stem cells in patients with chronic myeloid leukemia after mobilization with high-dose hydroxyurea].
Ojeda Gutiérrez E; Arrieta Gallastegui R; Bustos JG; Pérez Piño T; Rocha R; Sánchez Godoy P; Lozano M; Bello López JL; Hernández Navarro F
Sangre (Barc); 1997 Apr; 42 Suppl 1():21-3. PubMed ID: 9381295
[No Abstract] [Full Text] [Related]
24. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
25. Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML.
Weisser M; Schmid C; Schoch C; Hiddemann W; Kolb HJ
Bone Marrow Transplant; 2005 Dec; 36(11):1017-8. PubMed ID: 16184176
[No Abstract] [Full Text] [Related]
26. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
Perseghin P; Gambacorti-Passerini C; Tornaghi L; Dassi M; Pioltelli P; Parma M; Colnaghi F; Giudici G; Elli E; Fumagalli M; Ponchio L; Biondi A; Pogliani EM
Transfusion; 2005 Jul; 45(7):1214-20. PubMed ID: 15987369
[TBL] [Abstract][Full Text] [Related]
27. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
28. Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.
Tiribelli M; Marin L; Calistri E; Geromin A; Damiani D; Fanin R
Bone Marrow Transplant; 2004 Nov; 34(9):827-8. PubMed ID: 15334052
[No Abstract] [Full Text] [Related]
29. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
[TBL] [Abstract][Full Text] [Related]
30. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).
Schiffer CA; Hehlmann R; Larson R
Leukemia; 2003 Apr; 17(4):691-9. PubMed ID: 12682626
[TBL] [Abstract][Full Text] [Related]
31. [Successful induction of complete cytogenetic response with high-dose imatinib mesylate and subsequent allogeneic stem cell transplantation for CML blastic crisis].
Sugiyama K; Usui N; Asai O; Saito T; Yano S; Okawa Y; Takahara S; Takei Y; Uno S; Dobashi N; Kobayashi M
Rinsho Ketsueki; 2003 Jun; 44(6):386-90. PubMed ID: 12884817
[TBL] [Abstract][Full Text] [Related]
32. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
33. Role of allogeneic transplantation in chronic myeloid leukemia.
Heim D; Gratwohl A
Expert Rev Hematol; 2008 Oct; 1(1):41-50. PubMed ID: 21083006
[TBL] [Abstract][Full Text] [Related]
34. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
35. Best treatment option for infantile chronic myeloid leukemia patients: imatinib or hematopoietic stem cell transplantation?
Akcay A; Tugcu D; Aydogan G; Erbey F; Salcioglu Z; Akici F; Ozturk G
Pediatr Transplant; 2014 May; 18(3):316-7. PubMed ID: 24494789
[No Abstract] [Full Text] [Related]
36. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
Deshmukh C; Saikia T; Bakshi A; Amare-Kadam P; Baisane C; Parikh P
J Assoc Physicians India; 2005 Apr; 53():291-5. PubMed ID: 15987013
[TBL] [Abstract][Full Text] [Related]
37. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
38. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
Rea D; Legros L; Raffoux E; Thomas X; Turlure P; Maury S; Dupriez B; Pigneux A; Choufi B; Reman O; Stéphane D; Royer B; Vigier M; Ojeda-Uribe M; Recher C; Dombret H; Huguet F; Rousselot P; ;
Leukemia; 2006 Mar; 20(3):400-3. PubMed ID: 16437142
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
[TBL] [Abstract][Full Text] [Related]
40. [Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].
Meng FY; Sun J; Liu QF; Xu D; Yang LJ; Song LL; Liu XL; Xu B; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Dec; 23(12):1301-2, 1306. PubMed ID: 14678896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
